Subtopic Deep Dive
Perioperative Chemotherapy in Gastric Cancer
Research Guide
What is Perioperative Chemotherapy in Gastric Cancer?
Perioperative chemotherapy in gastric cancer administers neoadjuvant and adjuvant chemotherapy regimens around surgery to improve survival in resectable gastroesophageal adenocarcinoma.
Key trials like the FNCLCC/FFCD phase III trial by Ychou et al. (2011, 2053 citations) demonstrated perioperative fluorouracil plus cisplatin versus surgery alone increased overall survival. Foundational studies include van Hagen et al. (2012, 5317 citations) on preoperative chemoradiotherapy for esophageal or junctional cancer. Over 20 major papers establish multimodal protocols as standard.
Why It Matters
Perioperative chemotherapy standardizes treatment for resectable gastric cancer, showing 5-year survival gains in phase III trials (Ychou et al., 2011). It guides clinical guidelines like ESMO recommendations (Smyth et al., 2016; Lordick et al., 2022) and influences global protocols differing by region (Joshi and Badgwell, 2021). Pathological response predictors from these regimens enable personalized therapy, reducing recurrence rates in high-risk stage II-III cases (Sasako et al., 2011).
Key Research Challenges
Regional Treatment Variations
Eastern protocols favor adjuvant S-1 monotherapy post-surgery (Sasako et al., 2011, 1458 citations), while Western trials emphasize perioperative fluorouracil-cisplatin (Ychou et al., 2011). Reconciling these differences complicates global standardization. Japanese guidelines (2011, 2170 citations) highlight surgery-centric approaches absent in ESMO updates.
Pathological Response Prediction
Neoadjuvant regimens like ECF lack reliable predictors of tumor downstaging (van Hagen et al., 2012). Trials report variable complete response rates below 10% (Ychou et al., 2011). Integrating biomarkers remains unresolved in current guidelines (Lordick et al., 2022).
Toxicity and Compliance Issues
Perioperative chemotherapy yields acceptable adverse events but high dropout rates pre-surgery (Ychou et al., 2011). Chemoradiotherapy adds toxicity concerns (van Hagen et al., 2012, 5317 citations). Balancing efficacy with patient tolerance challenges regimen optimization.
Essential Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot et al. · 2012 · New England Journal of Medicine · 5.3K citations
Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. The regimen was associated with acceptable adverse-event rate...
Oesophageal carcinoma
Arjun Pennathur, Michael K. Gibson, Blair A. Jobe et al. · 2013 · The Lancet · 2.4K citations
Japanese gastric cancer treatment guidelines 2010 (ver. 3)
Unknown · 2011 · Gastric Cancer · 2.2K citations
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou, Valérie Boige, Jean‐Pierre Pignon et al. · 2011 · Journal of Clinical Oncology · 2.1K citations
Purpose After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluor...
Current treatment and recent progress in gastric cancer
Smita S. Joshi, Brian D. Badgwell · 2021 · CA A Cancer Journal for Clinicians · 1.7K citations
Abstract Gastric cancer is not a top‐10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern an...
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał et al. · 2021 · New England Journal of Medicine · 1.6K citations
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received n...
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elizabeth Smyth, Marcel Verheij, William Allum et al. · 2016 · Annals of Oncology · 1.6K citations
Reading Guide
Foundational Papers
Start with Ychou et al. (2011) for perioperative fluorouracil-cisplatin phase III OS data (HR 0.69); van Hagen et al. (2012) for chemoradiotherapy benchmarks; Sasako et al. (2011) for adjuvant S-1 5-year outcomes.
Recent Advances
Joshi and Badgwell (2021, 1665 citations) for global progress; Lordick et al. (2022) ESMO updates; Kelly et al. (2021) nivolumab adjuvant DFS extension.
Core Methods
Phase III RCTs compare perioperative ECF/fluorouracil-cisplatin vs. surgery; adjuvant S-1 monotherapy; pathological complete response via tumor regression grading; Kaplan-Meier OS/DFS with Cox HR.
How PapersFlow Helps You Research Perioperative Chemotherapy in Gastric Cancer
Discover & Search
Research Agent uses searchPapers and citationGraph on 'perioperative chemotherapy gastric cancer' to map 50+ papers, centering Ychou et al. (2011) with 2053 citations and its forward citations. exaSearch uncovers regional variants like Japanese S-1 trials; findSimilarPapers links to van Hagen et al. (2012) for junctional overlap.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Ychou et al. (2011), then runPythonAnalysis with pandas for hazard ratio computation and matplotlib survival plots. verifyResponse via CoVe cross-checks claims against Sasako et al. (2011); GRADE grading scores perioperative regimens as high-evidence for OS benefit.
Synthesize & Write
Synthesis Agent detects gaps in biomarker predictors across trials, flagging contradictions between perioperative ECF and adjuvant S-1. Writing Agent uses latexEditText for protocol tables, latexSyncCitations for 20-paper bibliographies, and latexCompile for guideline drafts; exportMermaid visualizes trial flowcharts.
Use Cases
"Extract and plot Kaplan-Meier survival curves from Ychou 2011 perioperative trial using Python."
Research Agent → searchPapers('Ychou perioperative') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas/matplotlib for OS/DFS curves) → researcher gets overlaid survival plots with HR=0.69.
"Draft ESMO-style guideline section on perioperative chemo for gastric cancer citing 15 trials."
Synthesis Agent → gap detection → Writing Agent → latexEditText('perioperative regimens') → latexSyncCitations(15 papers) → latexCompile → researcher gets compiled PDF with tables and references.
"Find code for gastric cancer pathological response models from related papers."
Research Agent → citationGraph(van Hagen 2012) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for tumor regression grading.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers → citationGraph on Ychou et al. (2011), generating structured reports with GRADE-scored OS meta-analysis. DeepScan applies 7-step CoVe verification to trial contradictions (perioperative vs. adjuvant), outputting checkpoint-validated summaries. Theorizer hypothesizes biomarker integration from van Hagen (2012) and Sasako (2011) data flows.
Frequently Asked Questions
What defines perioperative chemotherapy in gastric cancer?
It includes neoadjuvant chemotherapy before surgery and adjuvant after resection, using regimens like fluorouracil-cisplatin (Ychou et al., 2011).
What are key methods and regimens?
FNCLCC/FFCD trial used perioperative fluorouracil-cisplatin (Ychou et al., 2011); MAGIC trial ECF; Japanese use adjuvant S-1 (Sasako et al., 2011).
What are foundational papers?
Ychou et al. (2011, 2053 citations) for perioperative OS benefit; van Hagen et al. (2012, 5317 citations) for chemoradiotherapy survival gains; Sasako et al. (2011, 1458 citations) for S-1 adjuvant.
What open problems persist?
Biomarker predictors for pathological response; harmonizing perioperative Western vs. adjuvant Eastern protocols; immunotherapy integration post-resection (Kelly et al., 2021).
Research Gastric Cancer Management and Outcomes with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Perioperative Chemotherapy in Gastric Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.